Genetic Signatures Ltd
ASX:GSS

Watchlist Manager
Genetic Signatures Ltd Logo
Genetic Signatures Ltd
ASX:GSS
Watchlist
Price: 0.7 AUD -2.44% Market Closed
Market Cap: 158.8m AUD
Have any thoughts about
Genetic Signatures Ltd?
Write Note

Genetic Signatures Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genetic Signatures Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Genetic Signatures Ltd
ASX:GSS
Current Portion of Long-Term Debt
AU$392k
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Anteotech Ltd
ASX:ADO
Current Portion of Long-Term Debt
AU$627.3k
CAGR 3-Years
31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Proteomics International Laboratories Ltd
ASX:PIQ
Current Portion of Long-Term Debt
AU$95.4k
CAGR 3-Years
11%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
T
Trajan Group Holdings Ltd
ASX:TRJ
Current Portion of Long-Term Debt
AU$45.2m
CAGR 3-Years
75%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Cryosite Ltd
ASX:CTE
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
E
EZZ Life Science Holdings Ltd
ASX:EZZ
Current Portion of Long-Term Debt
AU$123.9k
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Genetic Signatures Ltd
Glance View

Market Cap
150.7m AUD
Industry
Life Sciences Tools & Services

Genetic Signatures Ltd. engages in the research and commercialization of identifying individual genetic signatures to identify diseases and disabilities. The company is headquartered in Sydney, New South Wales. The company went IPO on 2015-03-31. The firm is engaged in research and commercialization of identifying individual genetic signatures to aid in the diagnosis of infectious diseases and the sale of associated products into the diagnostic and research marketplaces. The firm is focused on the development and commercialization of its platform technology, 3Base. The Company’s 3Base platform technology provides hospital and pathology laboratories the ability to screen for an array of infectious pathogens, with a degree of specificity, in a rapid throughput (time-to-result) environment. The company also manufactures a Polymerase Chain Reaction (PCR) based products for the detection of infectious diseases under the EasyScreen brand. The Company’s EasyScreen sample processing kits are used to perform 3Base conversion and nucleic acid extraction and purification.

GSS Intrinsic Value
1.31 AUD
Undervaluation 46%
Intrinsic Value
Price

See Also

What is Genetic Signatures Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
392k AUD

Based on the financial report for Jun 30, 2024, Genetic Signatures Ltd's Current Portion of Long-Term Debt amounts to 392k AUD.

What is Genetic Signatures Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
5%

The average annual Current Portion of Long-Term Debt growth rates for Genetic Signatures Ltd have been 5% over the past three years .

Back to Top